Biocon Biologics Revenue, Valuation, Funding & Investors

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.

Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.

Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients for the chemical and pharmaceutical industry.

Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production, and sales of vaccines and biological products. The company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevention and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus, and other viruses, general drugs and other biological products, among others.

Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development. The company operates its business through three segments. The Pharmaceuticals segment focuses on the research and development, manufacturing, and sales of genetically engineered biologics, human vaccines, traditional Chinese medicines, and chemical pharmaceuticals. The Real Estate segment is involved in property development and sales. The Services segment provides scientific research and technical support, along with leasing and various business-related services. It generates the majority of its revenue from the Pharmaceuticals segment.

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Dong-E-E-Jiao Co Ltd is a China-based company engaged in the manufacturing and selling of Chinese herbs and traditional Chinese medicines, auxiliary materials for medicine, biological and healthcare products, and genetically engineered medicines. The company's main products include donkey-hide gelatin, compound donkey-hide gelatin paste, donkey-hide gelatin cake, instant donkey-hide gelatin powder, and others.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America.

Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.

Intas Pharmaceuticals is an Ahmedabad, India-based company ranked among India's top-10 pharmaceutical firms and the largest privately held in the country. The group manufactures generics, biosimilars, and value-added products across dosage forms like solid orals, injectables, and lyophilized preparations in over 10 facilities. Intas operates in 70 countries with major exports to the US, UK, and EU, holding the largest biosimilars portfolio commercialized in India and the first EU-launched biosimilar from an Indian firm.

LEO Pharma is a Ballerup-headquartered pharmaceutical company focused on medical dermatology. It develops therapies for psoriasis, atopic dermatitis, actinic keratosis, and other skin ailments. Key products include calcipotriol/betamethasone dipropionate combinations, IL-17 inhibitors, and topical treatments. Research occurs at facilities in Denmark, the United States, the United Kingdom, and Ireland. The firm distributes in over 100 countries through direct subsidiaries and licensing agreements. Founded in 1908.

Biomat USA is a network of plasma collection centers operated by Grifols producing source plasma for therapies treating hemophilia, immune deficiencies, and trauma. Centers in the United States offer donor compensation and community support programs, contributing to global supplies of albumin, immunoglobulins, and clotting factors.

Sinovac Life Sciences is a research-driven biopharma conducting vaccine R&D, production, and commercialization for human infectious diseases. Based in China, it focuses on viral pathogens through clinical trials, process scale-up, and regulatory filings. Operations mirror Sinovac Biotech efforts in formulation stability and large-scale filling for needle-free and traditional delivery systems.